Current DigitalHealth.London Accelerator company and DigitalHealth.London Evidence Generation Bootcamp alumnus, CyberLiver, has won “Rising Star” at the Digital Health Awards 2023. These awards, presented by the Digital Health Hub Foundation, took place during the Healthcare Ecosystem Platform (HLTH) global healthcare conference in Las Vegas.
The Digital Health Awards are dedicated to celebrating the significant advancements in healthcare through technology in the digital health sector. The event is divided into two distinct tracks, “Rising Stars” and “Best in Class”, to honour the exceptional contributions and breakthroughs shaping the future of healthcare.
This year, CyberLiver was honoured with the title of ‘Rising Star’ for their contributions in the Clinical Diagnostic Device, Platform, or Tool category.
CyberLiver integrates in-depth clinical hepatic research with cutting-edge sensor technology, machine learning, and artificial intelligence for better outcomes. Their scalable digital medicine platform offers personalized care through real-time monitoring, diagnosis, treatment, and management for a wide range of liver disease indications.
The company currently has “AlcoChange” for Alcohol Use Disorder (AUD) and alcohol-related liver disease (ARLD) and “CirrhoCare” for managing decompensated cirrhosis. With these technologies, CyberLiver aims to arrest or reverse the progression of liver disease, thereby improving patients’ quality of life and alleviating the strain on the healthcare system.
We are truly honoured and excited to be recognized at the Digital Health Hub Foundation Digital Health Awards 2023 in the Rising Star – Clinical Diagnostic Device, Platform, or Tool category. We thank the Digital Health Hub Foundation for acknowledging this significant unmet medical need in advanced liver disease, as well as the critical importance of providing innovative new digital intervention devices like AlcoChange and CirrhoCare to patients with advanced liver disease. This acknowledgement underscores our commitment to revolutionizing liver disease management through innovative digital solutions. At CyberLiver, we are dedicated to making a meaningful impact on patient care and advancing the field of digital health.Ravi Kumar
Co-founder and CEO of CyberLiver
The clinically safe and validated novel digital diagnostic and therapeutic approaches being developed by CyberLiver addresses huge unmet needs of patients with liver diseases. CirrhoCare is targeted at patients with advanced liver disease allowing them to be managed efficiently home. The award of the ‘Breakthrough Designation’ by the FDA will allow accelerated approval. AlcoChange delivers behavioural change interventions through the CyberLiver platform reducing alcohol consumption significantly in patients with alcohol related liver disease. Individually, they impact on the morbidity, mortality and costs of healthcare for these patients. The plasticity of the CyberLiver platform is being exploited to address the unmet needs of patients with steatotic liver diseases and those undergoing liver transplantation.Professor Rajiv Jalan
Co-founder and CMO of CyberLiver
Professor of Hepatology at University College London
Scientific Director of the European Foundation for the Study of Chronic Liver Failure
Cyberliver is currently on Cohort 7 of the DigitalHealth.London Accelerator programme. The company is also an alumnus of the DigitalHealth.London Evidence Generation Bootcamp programme.
The DigitalHealth.London Accelerator is a collaborative programme funded by the UK Government through the UK Shared Prosperity Fund, the Health Innovation Network South London, the Office of Life Sciences, CW+, the Mayor of London and the Levelling Up Fund.
The DigitalHealth.London Evidence Generation Bootcamp is for digital health companies that plan to launch or already have a product in the UK market and are committed to driving their evidence generation forward.